1. Multiplex analysis of genetic polymorphisms within UGT1A9, a gene involved in phase II of Δ9-THC metabolism
   Julia Sophie Schneider et al, 2018, Int J Legal Med CrossRef
2. The inhibition of UDP-glucuronosyltransferases (UGTs) by tetraiodothyronine (T4) and triiodothyronine (T3)
   Da-Wei Chen et al, 2018, Xenobiotica CrossRef
3. Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir
   Parul Patel et al, 2020 CrossRef
4. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms
   Akitomo Yokokawa et al, 2021, Eur J Drug Metab Pharmacokinet CrossRef
5. Effects of common genetic variants of human uridine diphosphate glucuronosyltransferase subfamilies on irinotecan glucuronidation
   Kouji Tagawa et al, 2022, Toxicology Mechanisms and Methods CrossRef
6. Nanoparticle-mediated therapeutic management in cholangiocarcinoma drug targeting: Current progress and future prospects
   Chunkang Liu et al, 2023, Biomedicine & Pharmacotherapy CrossRef
7. Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment
   Herman J. Woerdenbag et al, 2023, Cancers CrossRef
8. Cannabis Pharmacogenomics: A Path to Personalized Medicine
   Mariana Babayeva et al, 2023, CIMB CrossRef
9. UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment
   Cong Wang et al, 2024, Cancer Gene Ther CrossRef
10. Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by darolutamide: prediction of in vivo drug-drug interactions
    Shichao Xiao et al, 2024, Chemico-Biological Interactions CrossRef